People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Concordia International Corp. | — | Pharmaceuticals | Series D+ | $228.0M | $8.1B | 2018 |
Karl I. Belk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Karl I. Belk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Itzhak Krinsky | 1 | 2 |
| Randy Benson | 1 | 2 |
| Jeridean I. Young | 1 | 1 |
| Vikram I. Kamath | 1 | 1 |
| Robert I. Sully | 1 | 1 |
| Simon I. Tucker | 1 | 1 |
| Patrick I. Vink | 1 | 1 |
| Guy I. Clark | 1 | 1 |
| Francis I. Perier | 1 | 1 |
| Rochelle Fuhrmann | 1 | 1 |
| Adeel I. Ahmad | 1 | 1 |
| Paul I. Burden | 1 | 1 |
| Douglas Deeth | 1 | 1 |
| Graeme I. Duncan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.